Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol

Authors Domenico De Berardis, Nicola Serroni, Rosa Maria Salerno, Filippo Maria Ferro

Published 15 September 2007 Volume 2007:3(4) Pages 585—590

Domenico De Berardis1,2,3, Nicola Serroni2, Rosa Maria Salerno1, Filippo Maria Ferro1

1Department of Oncology and Neurosciences, Institute of Psychiatry, “G. D’Annunzio” University, Chieti, Italy. 2National Health Service, Department of Mental Health, SPDC Teramo, Italy. 3ITAB, Institute for Advanced Biomedical Technologies, “G. D’Annunzio” University Foundation, Chieti, Italy

Abstract: Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS). Pharmacologic options studied for treating severe PMS and PMDD may include selective serotonin reuptake inhibitors, anxiolytic agents, gonadotropin-releasing hormone agonists and the diuretic spironolactone. However, the use of combined oral contraceptives (COC) may be a therapeutic option in treating PMS and PMDD. The combination of drospirenone with ethinylestradiol (EE/drospirenone) was approved for marketing as an oral contraceptive in Europe and the United States. The preparation is characterized by a high contraceptive efficacy in combination with excellent cycle control, good tolerability, and a favourable impact on lipid and glucose metabolism. Recently, some placebo-controlled, randomized studies have tested clinical efficacy and tolerability of this COC in the treatment of PMDD. The aim of the present review was to elucidate the possible benefits or disadvantages of PMDD treatment with this novel formulation of EE/drospirenone. The results of trials evaluating the use of EE/drospirenone combination in the treatment of PMDD are encouraging but further studies are needed. However, the reported clinical efficacy and the relative good tolerability of EE/drospirenone may contribute to widen the therapeutic spectrum of PMDD.

Keywords: Premenstrual dysphoric disorder, oral contraceptives, drospirenone, ethinylestradiol, efficacy, tolerability.

Download Article [PDF] 

Readers of this article also read:

Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication

Jyothi KR, Beloor J, Jo A, Nguyen MN, Choi TG, Kim JH, Akter S, Lee SK, Maeng CH, Baik HH, Kang I, Ha J, Kim SS

International Journal of Nanomedicine 2015, 10:903-921

Published Date: 30 January 2015

Surface modifications of silica nanoparticles are crucial for their inert versus proinflammatory and immunomodulatory properties

Marzaioli V, Aguilar-Pimentel JA, Weichenmeier I, Luxenhofer G, Wiemann M, Landsiedel R, Wohlleben W, Eiden S, Mempel M, Behrendt H, Schmidt-Weber C, Gutermuth J, Alessandrini F

International Journal of Nanomedicine 2014, 9:2815-2832

Published Date: 5 June 2014

Causal diagrams and the logic of matched case-control studies

Shahar E, Shahar DJ

Clinical Epidemiology 2012, 4:137-144

Published Date: 15 May 2012

Did depressive symptoms affect recognition of emotional prosody in Parkinson’s disease?

Adriana Vélez Feijó, Carlos RM Rieder, Márcia LF Chaves

Neuropsychiatric Disease and Treatment 2008, 4:669-674

Published Date: 6 June 2008

A review of ramelteon in the treatment of sleep disorders

David N Neubauer

Neuropsychiatric Disease and Treatment 2008, 4:69-79

Published Date: 8 February 2008

Sleep disturbances and suicide risk: A review of the literature

Rebecca A Bernert, Thomas E Joiner

Neuropsychiatric Disease and Treatment 2007, 3:735-743

Published Date: 15 January 2008